A blood test that detects subtle changes in the nervous system could eventually reshape how clinicians investigate mental illness in children and adolescents. In a new study published in Translational Psychiatry, Pawlitzki, Masanneck, Schlarbaum and colleagues examine two promising serum biomarkers, neurofilament light chain, or NfL, and glial fibrillary acidic protein, or GFAP, in paediatric psychiatry. Their work addresses a long-standing problem: psychiatric diagnoses are generally based on interviews, behavioural observations and symptom histories, while the biological processes underlying those symptoms remain difficult to measure directly. By exploring molecules released from nervous-system cells into the bloodstream, the researchers are investigating whether psychiatry might gain objective biological signals that complement clinical assessment. The study does not turn a blood test into a diagnostic replacement, but it adds to a rapidly expanding effort to understand whether measurable changes in the brain and its supporting cells accompany psychiatric symptoms in young people.
NfL and GFAP provide information about different types of neural biology. Neurofilament light is one of the structural proteins that helps maintain the shape and internal organisation of axons, the long projections through which neurons transmit electrical signals. When axons are injured or stressed, fragments of neurofilament proteins can be released into surrounding fluid and eventually reach the blood. Because NfL is present in many nerve fibres, it is considered a relatively broad indicator of neuronal or axonal damage rather than a marker of one specific disease. GFAP, by contrast, is an intermediate filament protein found mainly in astrocytes, star-shaped cells that support neurons, regulate the chemical environment of the brain and participate in responses to injury and inflammation. Increased GFAP in blood may therefore reflect astrocytic activation or disturbance of the brain’s supporting tissue. The two proteins are not interchangeable: one is more closely linked to axonal integrity, while the other offers a window into glial responses.
The appeal of measuring these proteins in serum is practical as much as biological. Cerebrospinal fluid, collected through lumbar puncture, can provide a closer view of the central nervous system, but the procedure is invasive and difficult to justify for routine psychiatric research, particularly in children. Blood collection is faster, more familiar and potentially repeatable, allowing researchers to examine biological changes over time. Yet the very convenience of a blood test creates analytical challenges. NfL and GFAP occur at low concentrations in peripheral blood, so their measurement generally requires highly sensitive immunoassays capable of detecting tiny quantities of protein. Results can also be influenced by age, growth, physical activity, recent injuries, neurological disease, infection, metabolic health and the time between sample collection and analysis. A clinically meaningful interpretation must therefore distinguish a psychiatric association from the many other factors that can alter circulating biomarker levels.
The study’s importance lies in applying this biological framework to paediatric psychiatry, an area where objective laboratory measures are especially limited. Children and adolescents are not simply smaller versions of adults: their brains, immune systems and nervous systems are still developing, and biomarker concentrations may change naturally with age. Symptoms can also shift rapidly as development progresses. Anxiety, attention problems, mood disturbance, compulsive behaviour and psychotic experiences may overlap across diagnostic categories, making a single label an imperfect summary of a young person’s condition. NfL and GFAP could, in principle, help researchers ask more precise questions about whether particular symptom patterns are associated with neuronal stress, astrocytic responses or neither. The researchers’ examination of these markers therefore contributes to a broader move away from treating psychiatric diagnoses as biologically uniform categories and toward studying the underlying processes that may cut across them.
That possibility must be handled carefully. A raised NfL concentration would not, by itself, identify depression, attention-deficit/hyperactivity disorder, anxiety or any other psychiatric condition. NfL is a general marker of neural injury and can rise in many neurological circumstances, including trauma, inflammation and degenerative processes. GFAP is similarly broad and can be affected by biological responses that are not specific to mental illness. Even when levels differ between a clinical group and a comparison group, the difference may be too small to classify individual patients reliably. Researchers must also consider whether a biomarker reflects the psychiatric disorder itself, a co-occurring neurological or inflammatory process, medication exposure, sleep disruption, substance use, or the effects of stress. For this reason, serum markers are most likely to become useful as part of a wider clinical picture rather than as standalone tests.
The work also highlights the technical problem of translating group-level biology into individual care. In research, investigators may compare average biomarker concentrations across groups and determine whether the distributions differ statistically. In a clinic, however, the crucial question is whether a result can accurately inform a decision for one child. That requires validated reference ranges, reliable thresholds, high sensitivity and specificity, and evidence that the test improves outcomes. Age- and sex-related variation must be mapped carefully, as must differences between laboratories and assay platforms. A result that is meaningful in one research setting may not be directly comparable with a result produced elsewhere. Longitudinal studies will be essential because a single measurement cannot reveal whether a biomarker is stable, changing, related to symptom severity or responsive to treatment. The current study is therefore best understood as part of the validation process, not as the arrival of a ready-to-use diagnostic panel.
If future research confirms clinically useful patterns, the potential applications could extend beyond diagnosis. Repeated measurements might help identify young patients whose symptoms coincide with measurable changes in neural or glial biology, although that possibility remains to be demonstrated. Biomarkers could also help researchers divide broad diagnostic groups into biologically more coherent subgroups, making clinical trials more precise. In treatment studies, NfL and GFAP might be evaluated as indicators of safety, disease course or biological response, provided researchers can establish what changes mean and over what timescale. Such tools could support a more mechanistic form of paediatric psychiatry, in which symptoms are connected to measurable processes without reducing a child’s experience to a laboratory number. Any future clinical use would require careful communication, because biomarker results could cause anxiety, stigma or false reassurance if interpreted as definitive evidence of brain damage or illness.
The study arrives during a period of intense interest in blood-based indicators of brain health. Advances in ultrasensitive assays have made it possible to detect proteins once measurable only in cerebrospinal fluid, opening new routes for neurological and psychiatric research. But technological sensitivity does not automatically produce biological specificity. Detecting a molecule is only the first step; scientists must establish where it comes from, what process releases it, how it travels through the circulation and whether its concentration changes in a way that matters to patients. Paediatric studies face additional demands, including ethical recruitment, age-appropriate assessment and protection of children from unnecessary testing. The investigation by Pawlitzki and colleagues reflects both sides of this rapidly developing field: NfL and GFAP offer a scientifically plausible bridge between brain biology and blood testing, yet their meaning in psychiatric disorders must be determined through larger, carefully controlled and longitudinal investigations.
For now, the most significant message is not that a simple blood test can diagnose mental illness in children, but that paediatric psychiatry is beginning to examine biological signals with a level of precision once associated mainly with neurology. NfL and GFAP may help clarify whether some psychiatric presentations involve detectable changes in axons, astrocytes or broader nervous-system regulation. They may also reveal the limits of current biological models if expected differences fail to distinguish conditions or predict outcomes. The study’s contribution is to place these questions directly in the context of young patients, whose developmental stage makes both discovery and interpretation unusually complex. As evidence accumulates, the future of psychiatric assessment may combine careful clinical observation with molecular measurements, producing a richer picture of each patient while preserving the central role of experience, context and professional judgment.
Subject of Research: Serum biomarkers NfL and GFAP in paediatric psychiatry
Article Title: Exploring serum biomarkers in paediatric psychiatry: the impact of NfL and GFAP
Article References: Pawlitzki, M., Masanneck, L., Schlarbaum, L. et al. Exploring serum biomarkers in paediatric psychiatry: the impact of NfL and GFAP. Transl Psychiatry 16, 431 (2026). https://doi.org/10.1038/s41398-026-04347-1
Image Credits: AI Generated
DOI: 10.1038/s41398-026-04347-1
Keywords: paediatric psychiatry, serum biomarkers, neurofilament light chain, NfL, GFAP, astrocytes, neuronal injury, blood tests, mental health, neuroscience
